Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4Lymphoid 1

Conditions

Lymphoma 156Lymphoma, Non-Hodgkin 140Leukemia, Lymphocytic, Chronic, B-Cell 136Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Follicular 112Lymphoma, Large B-Cell, Diffuse 111Lymphoma, Mantle-Cell 75Lymphoma, B-Cell 73Hodgkin Disease 63Multiple Myeloma 58Leukemia 55Burkitt Lymphoma 51Recurrence 48Lymphoma, B-Cell, Marginal Zone 48Leukemia, Myeloid, Acute 47Neoplasms 45Myelodysplastic Syndromes 42Hematologic Neoplasms 34Waldenstrom Macroglobulinemia 28Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Lymphoma, T-Cell 17Leukemia, Biphenotypic, Acute 16Leukemia, B-Cell 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Mycosis Fungoides 15Lymphoproliferative Disorders 15Lymphoma, T-Cell, Peripheral 15Myeloproliferative Disorders 14Lymphoma, T-Cell, Cutaneous 14Breast Neoplasms 14

Interventions

BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Rhabdomyosarcoma, Alveolar × Lymphoid × Clear all
NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
31 enrolled 14 charts
LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon âš¡